


Curriculum Vitae

Name	Ross Andrew Soo	
Current Position & Affiliation	Senior Consultant, Department of Haematology-Oncology	
Country	Singapore	

Educational Background

MB BS (Monash)
PhD (University of Western Australia)
FRACP

Professional Experience

1. Senior Consultant, Department of Haematology-Oncology, National University Hospital
2. Visiting Consultant, Alexandra Hospital
3. Visiting Consultant, Ng Teng Fong General Hospital

Professional Organizations

1. Royal Australasian College of Physicians (RACP)
2. Singapore Society of Oncology (SSO)
3. American Society of Clinical Oncology (ASCO)
4. International Association for the Study of Lung Cancer (IASLC)
5. European Society for Medical Oncology (ESMO)
6. Australasian Lung Cancer Trials Group (ALTG)

Main Scientific Publications

1. Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. *J Thorac Oncol.* 2020 Sep;15(9):1484-1496.
2. Chan GH, Gwee YX, Low JL, Huang Y, Chan ZY, Choo JR, Ngoi NY, LE Ang Y, Muthu V, Chong WQ, Wong A, Soo RA. Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. *Lung Cancer.* 2020 Aug;146:145-153.
3. Peng S, Ying AF, Tai BC, Soo RA. A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. *Transl Lung Cancer Res.* 2020 Aug;9(4):1124-1137
4. Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. *Lancet Oncol.* 2019 Dec;20(12):1691-1701.
5. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. *Lancet Oncol.* 2017 Dec;18(12):e731-e741.